期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 854, 期 -, 页码 54-61出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2019.03.055
关键词
Asymmetric dimethylarginine; Dimethylarginine dimethylaminohydrolase; Tissue fibrosis
资金
- National Natural Science Foundation of China [81673432]
- Hunan Provincial Natural Science Foundation of China [2018JJ2543]
Fibrosis is a reparative process with very few therapeutic options to prevent its progression to organ dysfunction. Chronic fibrotic diseases contribute to an estimated 45% of all death in the industrialized world. Asymmetric dimethylarginine (ADMA), an endothelial nitric oxide synthase inhibitor, plays a crucial role in the pathogenesis of various cardiovascular diseases associated with endothelial dysfunction. Recent reports have focused on ADMA in the pathogenesis of tissue fibrosis. This review discusses the current knowledge about ADMA biology, its association with risk factors of established fibrotic diseases and the potential pathophysiological mechanisms implicating ADMA in the process of tissue fibrosis.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据